Showing results (221-230 of 280) with videos related to
Sort By:
Pageof 28
Plos One|May 29, 2019
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancerAndrew J Armstrong, Santosh Gupta, Patrick Healy, et al.European Urology Oncology|July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR TrialTian Zhang, Lauren Howard, Bridget F Koontz, et al.Cancer Medicine|September 15, 2023
Assessing the utility of molecular diagnostic classification for cancers of unknown primaryElle C Moore, Gerard C Blobe, Nicholas C DeVito, et al.Lancet (London, England)|February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K Pal, Catherine Tangen, Ian M Thompson, et al.Clinical Genitourinary Cancer|July 25, 2006
Development of an integrated prostate cancer research information systemWilliam K Oh, Julia Hayes, Carolyn Evan, et al.The Lancet. Oncology|September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trialCora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.British Journal of Cancer|November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.European Urology|October 3, 2017
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival ResultsRobert J Motzer, Alain Ravaud, Jean-Jacques Patard, et al.Pageof 28